## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 14A**

## PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. )

Filed by the Registrant 
Filed by a Party other than the Registrant 
Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under Rule 14a-12

_	Dem	inversion, Statement
	Defin	itive Additional Materials
$\boxtimes$	Solici	ting Material under Rule 14a-12
		GW PHARMACEUTICALS PLC (Name of Registrant as Specified In Its Charter)
		JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Paym	ent of F	iling Fee (Check the appropriate box):
$\boxtimes$	No fe	e required.
	Fee c	omputed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
	Fee p	aid previously with preliminary materials.
		k box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:

Explanatory Note: The following communications were made available by Jazz Pharmaceuticals or its officers through various social media accounts.



Yesterday, Jazz announced a definitive agreement to acquire GW Pharmaceuticals plc, which will strengthen our position as an innovative global biopharma company by combining our strengths with an industry leader in #cannabinoid science.

Important: bit.ly/3pOqBAU




8:47 AM · Feb 4, 2021 · Twitter Web App



•••

We are excited about this news and our transformation journey at Jazz

Pharmaceuticals. Jazz and GW Pharmaceuticals plc are focused on developing lifechanging medicines for people with serious diseases, often with limited or no
treatment options. Patients are at the center of what each company does. Jazz's and
GW's global teams possess unique talents and expertise and have proven capability
to develop and launch differentiated therapies to support often-overlooked patient
populations. Both companies are purpose-led and guided by shared values that
include integrity, collaboration, passion, innovation and pursuit of excellence, and
have cultures where diversity, equity and inclusion are a priority. Important:
https://lnkd.in/eG8NBjF



+ Follow

Today Jazz announced a definitive agreement to acquire GW Pharmaceuticals plc, a global leader in the science, development, manufacturing and commercialization of cannabinoid-based prescription medicines. ...see more



Bruce Cozadd
Chairman and Chief Executive Officer
Jazz Pharmaceuticals

We are joining two teams that share a passion for and track record of developing differentiated therapies that advance science and transform the lives of patients. This transaction will combine two global neuroscience companies both focused on critical, unmet patient needs.



## Read More

investor.jazzpharma.com • 14 min read